Stratos Wealth Partners’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $269K | Buy |
1,184
+11
| +0.9% | +$1.96K | ﹤0.01% | 1478 |
|
|
2026
Q1 | $202K | Sell |
1,173
-9
| -0.8% | -$1.67K | ﹤0.01% | 1532 |
|
|
2025
Q4 | $236K | Buy |
+1,182
| New | +$214K | ﹤0.01% | 1427 |
|
|
2025
Q1 | – | Sell |
-1,523
| Closed | -$281K | – | 1392 |
|
|
2024
Q4 | $281K | Sell |
1,523
-314
| -17% | -$60.5K | ﹤0.01% | 1173 |
|
|
2024
Q3 | $362K | Sell |
1,837
-348
| -16% | -$72.3K | 0.01% | 1061 |
|
|
2024
Q2 | $451K | Buy |
2,185
+237
| +12% | +$53.7K | 0.01% | 939 |
|
|
2024
Q1 | $528K | Sell |
1,948
-479
| -20% | -$114K | 0.01% | 872 |
|
|
2023
Q4 | $574K | Sell |
2,427
-78
| -3% | -$15.3K | 0.01% | 825 |
|
|
2023
Q3 | $491K | Buy |
2,505
+493
| +25% | +$101K | 0.01% | 827 |
|
|
2023
Q2 | $423K | Buy |
2,012
+123
| +7% | +$24.5K | 0.01% | 833 |
|
|
2023
Q1 | $381K | Sell |
1,889
-240
| -11% | -$54.4K | 0.01% | 786 |
|
|
2022
Q4 | $464K | Sell |
2,129
-60
| -3% | -$13.1K | 0.01% | 756 |
|
|
2022
Q3 | $431K | Sell |
2,189
-152
| -6% | -$32.8K | 0.01% | 744 |
|
|
2022
Q2 | $501K | Sell |
2,341
-159
| -6% | -$38.9K | 0.01% | 732 |
|
|
2022
Q1 | $710K | Buy |
2,500
+175
| +8% | +$54K | 0.02% | 671 |
|
|
2021
Q4 | $876K | Sell |
2,325
-178
| -7% | -$69.2K | 0.02% | 594 |
|
|
2021
Q3 | $1.03M | Buy |
2,503
+355
| +17% | +$147K | 0.03% | 514 |
|
|
2021
Q2 | $795K | Hold |
2,148
| – | – | 0.02% | 621 |
|
|
2021
Q1 | $623K | Buy |
2,148
+108
| +5% | +$30K | 0.02% | 641 |
|
|
2020
Q4 | $510K | Sell |
2,040
-43
| -2% | -$10.2K | 0.02% | 673 |
|
|
2020
Q3 | $472K | Sell |
2,083
-40
| -2% | -$8.3K | 0.02% | 638 |
|
|
2020
Q2 | $370K | Buy |
2,123
+83
| +4% | +$13.2K | 0.01% | 703 |
|
|
2020
Q1 | $257K | Hold |
2,040
| – | – | 0.01% | 735 |
|
|
2019
Q4 | $312K | Buy |
2,040
+50
| +3% | +$6.92K | 0.01% | 736 |
|
|
2019
Q3 | $263K | Hold |
1,990
| – | – | 0.01% | 773 |
|
|
2019
Q2 | $282K | Hold |
1,990
| – | – | 0.01% | 755 |
|
|
2019
Q1 | $289K | Hold |
1,990
| – | – | 0.01% | 729 |
|
|
2018
Q4 | $225K | Hold |
1,990
| – | – | 0.01% | 763 |
|
|
2018
Q3 | $268K | Buy |
1,990
+190
| +11% | +$23.4K | 0.01% | 754 |
|
|
2018
Q2 | $202K | Hold |
1,800
| – | – | 0.01% | 899 |
|
|
2018
Q1 | $192K | Sell |
1,800
-11
| -0.6% | -$1.19K | 0.01% | 919 |
|
|
2017
Q4 | $198K | Buy |
+1,811
| New | +$197K | 0.01% | 881 |
|
Other funds holding CRL
AI
Stratos Wealth Partners's CRL Position: Q2 2026 in Review
Stratos Wealth Partners increased its Charles River Laboratories (CRL) stake by 0.94% in Q2 2026, buying an estimated $1.96K and bringing the position to 1,184 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #1478.
Stratos Wealth Partners first reported a position in CRL in Q4 2017 and has held it in 32 quarters since. The position peaked at $1.03M in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Stratos Wealth Partners held 1,184 shares of Charles River Laboratories worth $269K as of Q2 2026.
- Stratos Wealth Partners bought 11 Charles River Laboratories shares in Q2 2026, an estimated $1.96K.
- Charles River Laboratories made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q2 2026, its #1478 holding.
- Stratos Wealth Partners first reported a position in Charles River Laboratories in Q4 2017 and has held it in 32 quarters since.
- Stratos Wealth Partners's Charles River Laboratories position peaked at $1.03M in Q3 2021.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.